Disc Medicine Buys Global Rights to Potential Oral Therapy for EPP

Disc Medicine Buys Global Rights to Potential Oral Therapy for EPP

296262

Disc Medicine Buys Global Rights to Potential Oral Therapy for EPP

Disc Medicine has entered into an exclusive worldwide licensing agreement to develop and commercialize Roche’s bitopertin, an oral candidate therapy for blood disorders. Disc will initially develop bitopertin for erythropoietic porphyrias, a group of porphyrias that mainly affect red blood cells and bone marrow. The company is planning to launch a Phase 2 trial in 2022 to test bitopertin in patients with erythropoietic protoporphyria (EPP), one of the three subtypes of erythropoietic porphyria. EPP is…

You must be logged in to read/download the full post.